Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Flexyn2a Vaccine in Healthy Adults
NCT02388009Phase 1Completed
- Sponsor
- LimmaTech Biologics
- Start
- Feb 2015
- Primary completion
- May 2015
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Flexyn2a in shigellosis (3 arms), sponsored by LimmaTech Biologics. Primary endpoint: Occurrence and severity of adverse events at Day 56. Started Feb 2015; status: completed.
02
Drugs
Flexyn2a
03
Conditions
shigellosis
Beyond the preview
Go deeper on NCT02388009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02388009.